Rhenman & Partners Asset Management AB Has $8.14 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Rhenman & Partners Asset Management AB decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 37.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,640 shares of the medical research company’s stock after selling 9,460 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Thermo Fisher Scientific were worth $8,136,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of TMO. Howard Capital Management Group LLC raised its position in Thermo Fisher Scientific by 0.5% in the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock valued at $33,759,000 after purchasing an additional 286 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Thermo Fisher Scientific by 22.1% during the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company’s stock worth $771,876,000 after acquiring an additional 225,568 shares during the last quarter. Integrated Wealth Concepts LLC increased its position in Thermo Fisher Scientific by 19.1% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 5,677 shares of the medical research company’s stock valued at $3,512,000 after acquiring an additional 912 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc lifted its position in shares of Thermo Fisher Scientific by 3.6% during the third quarter. Texas Capital Bank Wealth Management Services Inc now owns 802 shares of the medical research company’s stock worth $496,000 after purchasing an additional 28 shares in the last quarter. Finally, Temasek Holdings Private Ltd raised its position in Thermo Fisher Scientific by 0.3% in the 3rd quarter. Temasek Holdings Private Ltd now owns 1,071,180 shares of the medical research company’s stock worth $662,600,000 after purchasing an additional 2,813 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on TMO shares. Bank of America lowered their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Scotiabank upped their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research report on Monday, February 3rd. Wells Fargo & Company lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Finally, Raymond James reiterated an “outperform” rating and set a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $653.23.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $437.71 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm has a market cap of $165.13 billion, a price-to-earnings ratio of 26.48, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a one year low of $437.22 and a one year high of $627.88. The stock’s 50-day moving average is $532.01 and its 200-day moving average is $547.91.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a $0.43 dividend. The ex-dividend date is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.39%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is currently 10.41%.

Insider Activity at Thermo Fisher Scientific

In other news, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This represents a 26.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,900 shares of company stock valued at $13,106,062. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.